Artisan Mid Cap Value Fund Sold Bio-Rad Laboratories (BIO) in Q4
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Value Fund”. A copy of the letter can be downloaded here.
Bio-Rad Laboratories Inc. (BIO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sivik Global Healthcare Krishen Sud | 10,000 | $2,788 | -17% | 2.12% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $219.58 | 500 | $109,792.45 | 500 | 2017-05-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $306.18 | 700 | $214,288.51 | 510 | 2025-11-06 | Filing | |
| $247.06 | 3,000 | $741,184.20 | 8,171 | 2025-03-14 | Filing | |
| $329.94 | 3,000 | $989,815.20 | 7,559 | 2024-09-06 | Filing | |
| $330.49 | 623 | $205,898.14 | 147 | 2024-09-04 | Filing | |
| $281.91 | 369 | $104,023.46 | 6,573 | 2024-06-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 58,530 | $16,315,238 | 0.12% | |
| 2. | 9,320 | $2,597,951 | 0.25% | |
| 3. | 4,897 | $1,365,038 | 0.03% | |
| 4. | 1,247 | $347,601 | 0.02% | |
| 5. | 903 | $252,831 | 0% |
News See All
Disappointing Results Hurt Bio-Rad Laboratories (BIO)
Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf Partners Global Fund”. A copy of the letter can be downloaded here.
Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth
Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc.
10 Best Debt-Free Mid-Cap Stocks to Buy According to Hedge Funds
Mid-cap stocks are poised for an impressive run heading into the US midterm election.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Bio-Rad Fourth Quarter and Full Year 2025 Results Conference Call. At this time, I would like to hand things over to Mr. Edward Chung.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q3 2025 Earnings Call Transcript October 29, 2025Bio-Rad Laboratories, Inc. misses on earnings expectations.
Bio-Rad (BIO) Surged as the Earnings Exceeded Expectations
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here.
What Makes Bio-Rad Laboratories (BIO) an Investment Bet?
Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here.
Bio-Rad Laboratories, Inc. (BIO) Launches New Instruments, Boosts Molecular Testing Reach
A key growth driver is its droplet digital PCR (ddPCR) platform, led by the QX600 system.
13 Most Oversold Healthcare Stocks So Far in 2025
The healthcare innovation landscape in 2025 is navigating a complex mix of challenges and opportunities, marked by contrasting trends in fundraising, investment, and technology adoption.
Hedge Fund Resource Center